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ABSTRACT
Objective: The aim of this study was to collect pilot data on the magnitude of effect and toler-
ability of citalopram in early-onset major depressive disorder (MDD).
Method: This study was performed in two academic child and adolescent psychiatric clin-
ics (2000 through 2002). Thirty children and adolescents, 8–17 years of age (mean age, 13.57 
2.5), of both sexes (53.3% girls; 46.7% boys) and diagnosed with MDD by means of clinical
psychiatric evaluation, Diagnostic Interview for Children and Adolescents (DICA) and the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria, were
studied in an open-label clinical trial with 10–40 mg/day of citalopram for 6 weeks. The out-
come measures were the Hamilton Depression Rating Scale (HDRS), the Children Global As-
sessment Scale (CGAS), and the New York State Psychiatric Institute side-effect form.
Results: Moderate (50%–70% change in HDRS and CGAS) to large (> 70% change in HDRS
and CGAS) effect were seen in 91.7% of children (22/24). There were significant changes on
HDRS (X = 22.78; t = 14.12; p < 0.000) and CGAS (X = 26.02; t = 9.68; p < 0.000) between base-
line and the 6th week. Mild side effects were reported in 2 patients (8.3%). Adverse effects
that contributed to discontinuation were nausea and vomiting in 3.3% (n = 1) of patients and
unexpectedly switching to mania in 16.7% (n = 5) of patients.
Conclusion: Citalopram may be an efficatious treatment in early-onset MDD. However, the
high switch rate to mania warrants further investigations, as well as cautions, in using it.
INTRODUCTION
EARLY-ONSET (UNDER 18 YEARS OF AGE) major de-pressive disorder (MDD) is a common and
recurrent illness (Birmaher et al. 1996). The
prevalence of MDD ranges between 0.4% and
2.5% in children and between 0.4% and 8.3% in
adolescents (Fleming and Offord 1990; Kashani
et al. 1987a,b; Lewinsohn et al. 1994). Depression
in adults often begins in adolescence (Kessler
et al 1994; Lewinsohn et al. 1993a,b). Children
and adolescents with clinical depression have
high morbidity and mortality rates (Birmaher et
al. 1996). They experience impairment in school
performance and relationships with others
(Kovacs 1996; Kovacs et al. 1997; Puig-Antich
et al. 1993; Rohde et al. 1994). Depression in chil-
dren and adolescents contributes to increased
risk for suicidal behavior, homicide, tobacco use,
and substance abuse during later adolescence
1Unit on Child and Adolescent Psychiatry, Iran Hospital, Iran University of Medical Sciences, Tehran, Iran.
2Institute for Cognitive Studies, Tehran, Iran.
3Department of Child and Adolescent Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences,
Tehran, Iran.
13961C12.pgs  5/10/05  12:06 PM  Page 233
234 SHIRAZI AND ALAGHBAND-RAD
and adulthood, compared to individuals with-
out early-onset depression. They are at high risk
for physical illness, early pregnancy, exposure
to negative life events, and poor work perfor-
mance, as well as academic and psychosocial
functioning (Birmaher et al. 1996; Kovacs 1996;
Kovacs et al. 1997). There is also a secular in-
crease in the prevalence of MDD, and it ap-
pears that it is occurring at an earlier age in
successive cohorts, underscoring the necessity
for early identification and prompt treatment
interventions (Kovacs and Gatsonis 1994; Ryan
et al. 1992).
Controlled, double-blind trials have reported
no significant differences between placebo and
tricyclic antidepressants (TCAs), reporting a
40%–60% response rate to both (Hughes et al.
1990; Kashani et al. 1984; Petti and Law 1982;
Puig-Antich et al. 1987). Selective serotonin re-
uptake inhibitors (SSRIs) are efficacious for the
treatment of adults (Thase and Kupfer 1996)
and youths (Emslie et al. 1997) with MDD. They
have a relative benign side-effect profile, very
low mortality after an overdose, and suitabil-
ity for long-term maintenance (De Vane and
Sallee 1996; Kutcher 1997; Leonard et al. 1997;
Preskorn 1994). In open studies, 70%–90% of
adolescents with MDD show a treatment re-
sponse to SSRIs (De Vane and Sallee 1996;
Leonard et al. 1997; Rey-Sanchez and Gutier-
rez-Casares 1997). An 8-week, double-blind,
placebo-controlled trial of fluoxetine in 96 chil-
dren and adolescents with nonpsychotic MDD
showed significantly better response to fluoxe-
tine than placebo (56% versus 33%), with 31%
achieving full remission (Emslie et al. 1997).
Citalopram, which is the most selective SSRI,
is indicated for treatment of depression in
several countries (Keller 2000). Double-blind,
placebo-controlled studies have proven the ef-
ficacy of citalopram in treating MDD in adults
(Montgomery et al. 1993; Mendels et al. 1999).
Compared to the TCAs, citalopram shows a su-
perior side-effect profile and a more rapid onset
of action (Shaw et al. 1986). It has several po-
tential advantages over other SSRIs. It is re-
ported to have fewer side effects (Baldwin and
Johnson 1995) and lesser drug reactions than
other SSRIs (Greenblatt et al. 1998; Montgomery
1998; Nemeroff et al. 1996; Keller et al. 2001).
There have been a few studies evaluating citalo-
pram’s efficacy in children and adolescents
with MDD (Baumgartner et al. 2002; Bostic et
al. 2001). Our study was designed to collect
preliminary data on the effectiveness and toler-
ability of citalopram in children and adoles-
cents with MDD.
METHOD
Subjects were children and adolescents (under
18 years of age) of both genders who were ad-
mitted to the child and adolescent psychiatric
clinics of Roozbeh and Iran hospitals (two re-
ferral centers affiliated with Tehran and Iran
University) during 2000–2002.
To be included in this study, subjects had to
meet criteria of the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-
IV) for major depressive disorder (MDD), had
to be in good medical health, and had to have
normal intelligence. In addition to a structured
psychiatric interview, the initial evaluation in-
cluded a medical review of systems, a physical
and neurological examination, electroencepha-
lography (EEG) (to exclude seizure disorders),
electrocardiography (ECG), and laboratory tests
(complete blood-cell and differential-cell count,
urinalysis, thyroid function tests, liver function
tests, fasting blood sugar, cholesterol, triglyc-
eride, blood urea nitrogen, and creatinine). They
were screened for other psychiatric disorders,
using the Diagnostic Interview of Children and
Adolescents (DICA). Diagnosis was made by a
certified child and adolescent psychiatrist, based
on information from interviews of the parent
and child.
Exclusion criteria were all known organic pa-
thologies presenting with depressive or con-
founding symptoms. A full-scale IQ below 70
(mental retardation) was excluding as well. Two
subjects were not enrolled in the study because
of organic pathologies, which were grand mal
epilepsy in one of the subjects and minor tha-
lasemia in the other. Written, informed consent
and assent to participate in the study were ob-
tained from parents and corresponding patients.
Before entering the study, any subjects on
psychotropic medications were required to dis-
continue them for at least 2 weeks before the
study began.
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Depressive symptom severity was assessed
using the Hamilton Depression Rating Scale
(HDRS) because it is available in Farsi. Overall,
functioning was assessed using the Children’s
Global Assessment Scale (CGAS). The New
York State Psychiatric Institute side-effect form
for clinical trial in children and adolescents
was used to assess medication side effects.
The treatment phase of this study consisted
of a 6-week, open label medication trial after a
2-week washout period for subjects previously
on psychotropic medications. The duration of
6 weeks is one of the recommended durations
for open clinical trials in children and adoles-
cents with depression (Klein et al. 1994). Citalo-
pram was initiated at 10–20 mg per day in the
morning determined by clinician’s judgment.
The medication was prescribed by the psychi-
atrist, and the dosage was adjusted on an indi-
vidual basis at 10–40 mg per day. The dose
schedule was designed to be stabilized by week
6. Compliance was evaluated by pill count.
The psychiatrist maintained weekly contacts
(or more, if indicated) with the subjects and/
or parents. At these times, weekly ratings of
HDRS, CGAS, side-effect form, and pill count
were completed. Detailed progress notes were
recorded after each visit as well.
A paired t test was applied to compare the pre-
and posttreatment ratings. A p value of <0.05
was chosen to represent statistical significance.
RESULTS
Of the initial 30 subjects, 24 subjects com-
pleted the study. Demographic, clinical charac-
teristics and comorbid diagnoses of the sample
are summarized in Table 1.
The average daily dose of citalopram was
20.8 mg, with a range of 10–40 mg per day. At
the end of the study, 2 subjects (8.3%) were tak-
ing 10 mg per day, 20 subjects (83.3%) were
taking 20 mg per day, and the other 2 subjects
(8.3%) were taking 40 mg per day.
Therapeutic effects
Table 2 and Figure 1 show responses to med-
ication from baseline through week 6. There
were significant changes on outcome measures
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between baseline and 6 weeks of treatment with
citalopram. None of the subjects met criteria
for MDD at the end of the study.
Table 3 summarizes the range of changes in
HDRS and CGAS. As Table 3 shows, moderate
(50%–70%) to large (> 70%) improvements are
seen in 91.7%.
Adverse effects
No statistically significant changes were
found in weight, height, or vital signs. Three
subjects (10%) reported mild side effects, which
resolved spontaneously or with dosage adjust-
ment. They were delayed menstrual period, di-
uresis, nausea, and diaphoresis. Physical side
effects, as a reason for discontinuation, occurred
in only 1 patient who developed gastrointesti-
nal complications; mainly, nausea and vomit-
ing. No suicidal thoughts or behaviors were
reported in the sample during the study.
Five patients (16.7%) discontinued the med-
ication because of their switching to mania,
which was significantly high. They were 3 boys
and 2 girls with a mean age of 12.6 (1.92) years.
All of the patients were experiencing their first
episode of depression and 1 patient had obses-
sive-compulsive disorder and tic disorder as a
TABLE 1. CLINICAL CHARACTERISTICS OF MDD SAMPLE
Features (N = 30)
Demographic
Age, year range 8–17
Age, mean (±SD) 13.57 (±2.5)
Female, N(%) 16 (53.3%)
Male, N(%) 14 (46.7%)
Primary school, N(%) 6 (20%)
High school, N(%) 24 (80%)
Clinical
Inpatient, N(%) 9 (30%)
Outpatient, N(%) 21 (70%)
Comorbid Diagnoses
Obsessive-compulsive disorder, N(%) 13 (43.3%)
Simple phobia, N(%) 9 (30%)
Generalized anxiety disorder, N(%) 5 (16.7%)
Oppositional-defiant disorder, N(%) 3 (10%)
Tic disorder, N(%) 2 (6.7%)
Attention-deficit/hyperactivity 2 (6.7%)
disorder, N(%)
MDD, major depressive disorder; N, number of
patients; SD, standard deviation.
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comorbidity. They were taking 20 mg of citalo-
pram per day from the beginning of the study
and showed a full manic picture during the
2nd week.
All subjects who completed the study in-
tended to continue the medication, although the
high cost of medication was a major concern.
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DISCUSSION
Citalopram treatment was effective in reliev-
ing early-onset depressive symptoms, and this
was evident in CGAS and HDRS. Differences
before and 6 weeks after the onset of treatment
were statistically significant on both scales.
TABLE 2. MEAN AND STANDARD DEVIATION (SD) SCORES OF MDD SAMPLE BEFORE AND
AFTER 6 WEEKS TREATMENT OF CITALOPRAM
Baseline Six weeks paired T test
(N = 30) (N = 24)
Measure Mean score SD Mean score SD df t-score p-value
HDRS 32.9 ±8.4 10.12 ±7.5 23 14.12 <0.000
CGAS 39.9 ±8.4 65.92 ±12.3 23 9.68 <0.000
HDRS, Hamilton Depression Rating Scale; CGAS, Children Global Assessment Scale; MDD, major depressive
disorder.
FIG. 1. Mean (X) and standard deviation (SD) of HDRS and CGAS scales before and after 6 weeks treatment of
citalopram.
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There was no clear difference in patient respon-
siveness based on age or gender. When review-
ing the weekly ratings in this study, it was
noted that most subjects showed improvement
within 1–2 weeks after the onset of medication,
consistent with adult studies comparing citalo-
pram to other SSRIs, such as fluoxetine (Patris
et al. 1996) and sertraline (Stahl 1998).
Citalopram has little or no affinity for pre- or
postsynaptic receptors, such as those for dopa-
mine, norepinephrine, and histamine (Hyttel et
al. 1995). There are fewer complaints of side ef-
fects reported with citalopram use in other stud-
ies (Baldwin and Johnson 1995). In our study,
where subjects took between 10 to 40 mg per day
of citalopram, most adverse effects were mini-
mal and tended to resolve spontaneously. There
were no changes in vital signs as well. However,
our finding of a high switch rate from depression
to mania is alarming. Follow-up studies have
found that 20%–40% of children and adolescents
with MDD develop bipolar I disorder within a
period of 5 years after the onset of depression,
and early-onset depression is associated with an
increased risk of developing bipolar I disorder
(Geller and Luby 1997; Kovacs et al. 1997; Ko-
vacs 1996; Strober et al. 1995; Strober and Carl-
son 1982). Many youth referred for depression
are experiencing their first depressive episode.
Because the symptoms of unipolar and bipolar
depression are similar, it is difficult to determine
whether a patient needs only an antidepressant
or concomitant use of mood stabilizers. Some
patients have to discontinue the treatment be-
cause of switching to mania.
Limitations
As comorbid disorders were frequent, mea-
surements assessing other symptoms—not only
depression—might change differentially as a
function of treatment. The number of patients
in this study, however, did not allow evaluating
the responses according to coexisting disorders.
Future studies should take this into account by
examining subgroups.
Because of the limited duration in this study
(6 weeks), there may be an uncertainty whether
gains were stable. In addition, placebo effects
could have added to the effects observed.
CONCLUSION
The findings of this study suggest that citalo-
pram, at 10 to 40 mg per day, may be efficatious
in acute-phase treatment of MDD in children
and adolescents. However, adverse side effects
are of concern. Our findings are relevant to
clinicians who are faced with treatment deci-
sions for early-onset depression and a relative
limited data guiding therapeutic choice. Pro-
spective double-blind, controlled studies in-
volving placebo and other drug comparisons
in larger samples and longer durations are war-
ranted to confirm these findings.
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